Certified Principal Investigator (CPI®) — Questions and Answers

Question 1: An investigator receives new safety information from the sponsor about an increased risk associated with the investigational product. What is the MOST immediate obligation?

Wait for a protocol amendment before taking any action
Disregard unless FDA issues a formal safety alert
Assess the impact on enrolled subjects and notify the IRB in a timely manner (Correct answer)
Suspend enrollment until the IRB reviews the information

Correct answer: Assess the impact on enrolled subjects and notify the IRB in a timely manner

Investigators must promptly assess new safety information and report it to the IRB, as it may require consent form updates or protocol changes to protect subjects.

Question 2: A clinical investigator must ensure that all CRF data can be traced back to source documents. This principle is known as:

Source data traceability (Correct answer)
Blinding documentation
Data lock
Adverse event coding

Correct answer: Source data traceability

Source data traceability ensures that every CRF entry can be verified against its originating source document, supporting data integrity.

Question 3: When a research participant withdraws consent mid-trial, what is the investigator's primary obligation?

Continue data collection until the current study phase ends
Stop participation immediately and retain only already-collected data per protocol (Correct answer)
Require a 30-day cooling-off period before honoring the withdrawal
Destroy all previously collected data at once

Correct answer: Stop participation immediately and retain only already-collected data per protocol

Withdrawal must be honored immediately, but data already lawfully collected may be retained as specified in the IRB-approved protocol.

Question 4: A researcher is evaluating drug abuse potential for a CNS stimulant in a Phase I trial. Which endpoint is considered the regulatory gold standard for assessing subjective drug liking?

Addiction Severity Index (ASI) score
Visual Analog Scale (VAS) for drug liking at peak effect (Emax) (Correct answer)
Digit Symbol Substitution Test (DSST)
Hamilton Anxiety Rating Scale (HAM-A)

Correct answer: Visual Analog Scale (VAS) for drug liking at peak effect (Emax)

FDA and EMA guidance for human abuse potential studies specifies VAS Drug Liking Emax as the primary endpoint for comparing subjective reinforcing effects to a reference drug.

Question 5: Which regulatory pathway allows emergency use of an unapproved drug outside of a clinical trial when no alternatives exist?

Emergency IND waiver under 21 CFR 312.44
FDA Emergency Use Authorization under 21 CFR 601
Institutional emergency authorization under IRB guidelines
Expanded access (compassionate use) under 21 CFR 312.310 (Correct answer)

Correct answer: Expanded access (compassionate use) under 21 CFR 312.310

21 CFR 312.310 governs individual patient expanded access (compassionate use) for emergency situations where no alternatives are available.

Question 6: A subject misses a scheduled assessment window for a key efficacy endpoint. The study team obtains the assessment 5 days outside the protocol window. How should this be handled?

Discard the out-of-window data as it cannot be used
Document the deviation, collect the assessment, and report the protocol deviation per site procedures (Correct answer)
Continue as if no deviation occurred and record the visit as on-time
Withdraw the subject from the study immediately

Correct answer: Document the deviation, collect the assessment, and report the protocol deviation per site procedures

Out-of-window assessments should still be collected for subject safety, documented as a protocol deviation, and reported according to site and sponsor procedures.

Question 7: What is a near-miss report in CPI practice?

Documentation of an event that could have caused harm but did not (Correct answer)
An employee near target
A near break-even report
A project near deadline

Correct answer: Documentation of an event that could have caused harm but did not

Near-miss reports document events where harm almost occurred, providing data to prevent future incidents.

Question 8: Under what circumstance must an investigator obtain re-consent from an existing research subject?

When the study reaches its halfway enrollment milestone
When the IRB membership changes
When a protocol amendment introduces new risks or changes that may affect willingness to continue (Correct answer)
Annually regardless of study changes

Correct answer: When a protocol amendment introduces new risks or changes that may affect willingness to continue

Re-consent is required when protocol amendments introduce significant new information—such as new risks or changes to procedures—that could affect a subject's decision to continue.

Question 9: A subject enrolled in a cancer trial develops a grade 3 adverse event that is not listed in the protocol's dose modification table. What should the investigator do?

Follow standard of care guidelines and proceed without notifying the sponsor
Use clinical judgment and document the rationale for any dose change
Discontinue the subject from the trial immediately
Contact the sponsor's medical monitor for guidance before making any change (Correct answer)

Correct answer: Contact the sponsor's medical monitor for guidance before making any change

When protocol guidance is absent, the investigator should contact the sponsor's medical monitor to ensure consistent decision-making across sites.

Question 10: The principal investigator delegates source document review and CRF completion to a sub-investigator. This delegation must be:

Documented on a delegation of authority log with the date and scope of delegation (Correct answer)
Approved by the FDA before the sub-investigator may act
Verbally communicated to all site staff
Re-delegated each calendar year regardless of staff changes

Correct answer: Documented on a delegation of authority log with the date and scope of delegation

All task delegations must be recorded on a delegation of authority log, specifying who is delegated, what tasks, and when the delegation begins and ends.

Question 11: What action is required when a shipment of investigational product arrives at the clinical site?

Repackage in study-blind containers before logging receipt
Inspect shipment, verify contents against shipping manifest, and document receipt in accountability log (Correct answer)
Return unopened to sponsor until IRB approval is confirmed
Immediately distribute to subjects to avoid storage fees

Correct answer: Inspect shipment, verify contents against shipping manifest, and document receipt in accountability log

Upon receipt, site staff must inspect the shipment for damage, verify contents against the shipping manifest, check storage conditions during transit, and document the receipt in the drug accountability log.

Question 12: Which of the following is considered a source document in a clinical trial?

The original hospital medical record containing lab results (Correct answer)
The protocol synopsis distributed to IRB members
The sponsor's monitoring visit report
The completed CRF submitted to the sponsor

Correct answer: The original hospital medical record containing lab results

Source documents are original records from which CRF data are transcribed, including hospital charts, lab reports, and clinic notes.

Question 13: Which action by a CPI constitutes research fraud under federal regulations?

Requesting a protocol amendment to add a new enrollment site
Intentionally falsifying source documents to match case report forms (Correct answer)
Asking an IRB for a waiver of documentation of consent
Reporting an unexpected serious adverse event to the FDA

Correct answer: Intentionally falsifying source documents to match case report forms

Falsifying source documents is research fraud, violating FDA regulations, GCP, and professional ethical standards.

Question 14: Under 21 CFR 50.25, which of the following is classified as an ADDITIONAL element of informed consent (rather than a basic required element)?

A description of foreseeable risks or discomforts to the participant
Disclosure that a particular treatment or procedure may involve currently unforeseeable risks to a participant or embryo if pregnant (Correct answer)
A statement that records may be inspected by FDA
An explanation of the purpose of the research

Correct answer: Disclosure that a particular treatment or procedure may involve currently unforeseeable risks to a participant or embryo if pregnant

The disclosure of unforeseeable risks to participants or embryos is listed under 21 CFR 50.25(b) as an additional element, not a basic required one.

Question 15: The Karnofsky Performance Status scale scores subjects from 0 to 100. A subject who requires occasional assistance but can care for most personal needs has a Karnofsky score of approximately:

70 (Correct answer)
50
100
80

Correct answer: 70

A Karnofsky score of 70 describes a subject who cares for themselves but is unable to carry on normal activity or active work, requiring occasional assistance.

Question 16: RECIST 1.1 criteria for tumor response assessment classify a ≥30% decrease in the sum of diameters of target lesions as:

Progressive Disease (PD)
Partial Response (PR) (Correct answer)
Complete Response (CR)
Stable Disease (SD)

Correct answer: Partial Response (PR)

RECIST 1.1 defines Partial Response (PR) as at least a 30% decrease in the sum of diameters of target lesions compared to baseline.

Question 17: The ALCOA-C principles for clinical data integrity stand for:

Accountable, Logical, Contemporaneous, Organized, Accurate — Correct
Auditable, Legible, Compliant, Organized, Accurate — Consistent
Attributable, Legible, Contemporaneous, Original, Accurate — Complete (Correct answer)
Accurate, Legible, Consistent, Original, Attributable — Complete

Correct answer: Attributable, Legible, Contemporaneous, Original, Accurate — Complete

ALCOA-C stands for Attributable, Legible, Contemporaneous, Original, Accurate, and Complete — the FDA's foundational principles for data integrity.

Question 18: Under ICH E6(R2) GCP guidelines, the protocol must include which of the following regarding treatment?

Description of investigational product, dose, schedule, route, and duration (Correct answer)
Insurance coverage terms for study-related injuries
Marketing strategy for the investigational product post-trial
Investigator's personal clinical experience with similar treatments

Correct answer: Description of investigational product, dose, schedule, route, and duration

ICH E6(R2) requires the protocol to specify the investigational product's dose, dosage regimen, route of administration, and treatment duration.

Question 19: What is the role of a sponsor's Clinical Research Associate (CRA) during a drug accountability monitoring visit?

To randomize new subjects into the trial
To dispense investigational product directly to enrolled subjects
To update the informed consent form based on new safety data
To verify that IP records are complete, accurate, and that physical inventory matches the accountability log (Correct answer)

Correct answer: To verify that IP records are complete, accurate, and that physical inventory matches the accountability log

During monitoring visits, the CRA reviews drug accountability records and performs a physical count of IP to verify that quantities on hand match what the log indicates should be remaining.

Question 20: A clinical trial protocol uses an 'adaptive design' with response-adaptive randomization. What is a key regulatory concern with this approach?

Requirement for a larger control group than experimental group
Inability to use the trial data for regulatory submissions
Increased cost of drug supply due to unpredictable allocation ratios
Potential for operational bias if allocation changes are not properly blinded and controlled (Correct answer)

Correct answer: Potential for operational bias if allocation changes are not properly blinded and controlled

Adaptive randomization can introduce operational bias if the changing allocation ratios are not masked from site staff or properly controlled.

Question 21: What are principles of good documentation in CPI?

Include personal opinions
Speed is the only factor
Only document positives
Accuracy, completeness, timeliness, objectivity, and legibility (Correct answer)

Correct answer: Accuracy, completeness, timeliness, objectivity, and legibility

Good documentation must be accurate, complete, timely, objective, and legible.

Question 22: What is the importance of informed consent in clinical research?

To reduce research costs
To increase recruitment
To speed up data collection
To ensure participants understand the study and risks involved (Correct answer)

Correct answer: To ensure participants understand the study and risks involved

Informed consent is a fundamental ethical principle in clinical research, ensuring that potential participants voluntarily agree to participate after fully understanding the study's purpose, procedures, potential risks, and benefits. This process empowers individuals to make autonomous decisions about their involvement and protects their rights.

Question 23: In a double-blind randomized controlled trial, an investigator unblinding data for personal review of outcomes before trial completion is:

Permissible when fewer than 10% of subjects remain enrolled
Standard practice for quality assurance purposes
Acceptable if the investigator is also a treating physician
A serious protocol deviation that could bias results and must be reported (Correct answer)

Correct answer: A serious protocol deviation that could bias results and must be reported

Unauthorized unblinding compromises study integrity, introduces bias, and constitutes a protocol deviation requiring immediate reporting.

Question 24: A site uses paper CRFs but also maintains an electronic laboratory information system (LIS). For source data verification purposes, the LIS printouts are considered:

Secondary documents that cannot serve as source
Inadmissible because they are not handwritten
Certified copies that may serve as source if they are accurate reproductions of the original (Correct answer)
Acceptable only for non-critical data points

Correct answer: Certified copies that may serve as source if they are accurate reproductions of the original

Certified copies that accurately reproduce all original content can serve as source documents per ICH E6(R2) guidance on source data.

Question 25: A participant in a Phase II oncology trial loses decision-making capacity mid-study after enrollment. What is the APPROPRIATE next step?

Continue the trial without any modification since consent was already obtained
Withdraw the participant from the study immediately per regulatory mandate
Seek consent from a legally authorized representative (LAR) and assess whether continued participation is in the participant's best interest (Correct answer)
Contact FDA for a waiver of continuing consent requirements

Correct answer: Seek consent from a legally authorized representative (LAR) and assess whether continued participation is in the participant's best interest

When a participant loses capacity, a LAR must provide permission for continued participation, and the investigator must assess whether continued participation benefits or harms the participant.

Question 26: In a clinical trial, what is the primary purpose of using a double-blind design when collecting outcome data?

To reduce sample size requirements
To simplify the randomization process
To eliminate bias from both participant and assessor expectations (Correct answer)
To ensure all participants receive active treatment

Correct answer: To eliminate bias from both participant and assessor expectations

Double-blind design prevents both participants and outcome assessors from knowing treatment assignment, minimizing performance and detection bias.

Question 27: What role do standard operating procedures play in CPI Patient Assessment & Evaluation?

Satisfying management only
Creating unnecessary paperwork
Ensuring consistency and quality through documented instructions (Correct answer)
Restricting creativity

Correct answer: Ensuring consistency and quality through documented instructions

SOPs provide standardized instructions ensuring consistent quality regardless of which qualified person performs the work.

Question 28: After an emergency unblinding event, which action must the investigator take regarding the IRB?

Notify the IRB and sponsor of the unblinding event and its circumstances (Correct answer)
Notify the IRB only at the next scheduled continuing review
Notify the IRB only if the event was fatal
No notification is required if the participant recovered fully

Correct answer: Notify the IRB and sponsor of the unblinding event and its circumstances

Investigators must promptly report emergency unblinding events to both the IRB and sponsor, documenting the reason and outcome.

Question 29: When a clinical trial requires a HIPAA Authorization, which of the following is a required element that distinguishes it from a general informed consent form?

The investigator's professional license number
A summary of competing sponsor interests
A description of the study's primary endpoint
A list of the types of protected health information to be used or disclosed (Correct answer)

Correct answer: A list of the types of protected health information to be used or disclosed

HIPAA Authorization must specifically describe the protected health information (PHI) to be used or disclosed, which is distinct from general informed consent requirements.

Question 30: What is a 'short form' written consent document?

An abbreviated consent used for telephone screening
A document stating that required elements were presented orally and the subject agrees (Correct answer)
A consent form approved for use without IRB review
A one-page summary replacing the full consent form for low-risk studies

Correct answer: A document stating that required elements were presented orally and the subject agrees

A short form consent document states that the elements of informed consent were orally presented to the subject or LAR, and requires a witness signature and written summary of what was presented.

Question 31: A protocol specifies treatment until 'disease progression or unacceptable toxicity.' A subject's imaging shows stable disease but the subject reports significantly worsening quality of life. Should the investigator discontinue treatment?

Yes, if the deterioration meets the protocol's definition of 'unacceptable toxicity' or falls under investigator clinical judgment criteria (Correct answer)
No, because stable disease means the subject must continue per protocol
No, because quality of life is not a valid reason to discontinue treatment in a clinical trial
Yes, because any subject complaint requires immediate treatment discontinuation

Correct answer: Yes, if the deterioration meets the protocol's definition of 'unacceptable toxicity' or falls under investigator clinical judgment criteria

Significant quality of life deterioration may meet protocol-defined unacceptable toxicity criteria or fall within the investigator's discretion to discontinue in the subject's best interest.

Question 32: A subject enrolled in a clinical trial becomes pregnant during the study. What is the investigator's typical obligation?

Allow the subject to remain on study drug throughout the pregnancy
Follow the protocol's pregnancy management plan, which usually includes discontinuing the investigational product and reporting the pregnancy (Correct answer)
Report only if a congenital anomaly is confirmed after delivery
Transfer care of the subject to an obstetrician with no further study involvement

Correct answer: Follow the protocol's pregnancy management plan, which usually includes discontinuing the investigational product and reporting the pregnancy

Most protocols require investigational product discontinuation in pregnancy with follow-up reporting per the pregnancy management plan, as fetal risk is typically unknown.

Question 33: A clinical trial site receives a sponsor audit. The auditor finds that source documents are missing for 3 participants. What is the regulatory implication?

The study must be terminated immediately by FDA mandate
Missing source documents constitute a data integrity failure that may trigger FDA inspection and clinical hold (Correct answer)
The sponsor must reimburse the site for document recovery costs
Participants must be re-consented to replace missing documentation

Correct answer: Missing source documents constitute a data integrity failure that may trigger FDA inspection and clinical hold

Missing source documents undermine data integrity and verifiability, and can result in sponsor corrective actions, FDA inspection, or rejection of submitted data.

Question 34: A researcher finds that a participant in an immunosuppression trial tested positive for latent tuberculosis (LTBI) at screening. Before initiating the investigational drug, the MOST appropriate action is:

Initiate LTBI treatment and delay trial enrollment until treatment is complete
Exclude the participant from the trial
Consult with an infectious disease specialist and follow the protocol's guidance (Correct answer)
Administer prophylactic isoniazid concurrently with the investigational drug

Correct answer: Consult with an infectious disease specialist and follow the protocol's guidance

Management of LTBI in immunosuppression trials should be guided by an infectious disease specialist and the protocol's pre-specified guidance for this scenario.

Question 35: After emergency treatment alters a participant's study assessments (e.g., steroids given for anaphylaxis affect a biomarker endpoint), the investigator must:

Document the emergency treatment and concomitant medications fully so data integrity is preserved (Correct answer)
Withdraw the participant and delete their data
Exclude all affected data from the final analysis without documentation
Administer compensatory doses of study drug to normalize biomarker levels

Correct answer: Document the emergency treatment and concomitant medications fully so data integrity is preserved

All concomitant emergency treatments must be documented so data analysts can appropriately account for confounders while preserving data integrity.

Question 36: Why is accurate documentation important in CPI?

Only for medical/legal fields
It supports decision-making, compliance, and legal defensibility (Correct answer)
No impact on quality
Only for bureaucratic purposes

Correct answer: It supports decision-making, compliance, and legal defensibility

Accurate documentation supports quality assurance, compliance, legal defensibility, and knowledge continuity.

Question 37: A participant who was lost to follow-up contacts the site reporting a hospitalization that occurred two months ago. The investigator should:

Report it only to the sponsor but not to the IRB since it is retrospective
Reopen the participant's case only if the event was fatal
Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria (Correct answer)
Ignore the event because it was not reported within the protocol's SAE window

Correct answer: Assess the event for seriousness, document it thoroughly, and report if it meets SAE criteria

Retrospective SAE reports must still be assessed, documented, and reported if they meet SAE criteria; there is no regulatory exemption for late discovery.

Question 38: How does professional liability insurance protect CPI practitioners?

Protecting against equipment theft
Covering disaster damage
Paying health premiums
Covering financial losses from claims of negligence or errors (Correct answer)

Correct answer: Covering financial losses from claims of negligence or errors

This insurance covers financial consequences of claims alleging negligence or mistakes in professional services.

Question 39: What role do standard operating procedures play in CPI Infection Control & Prevention?

Ensuring consistency and quality through documented instructions (Correct answer)
Creating unnecessary paperwork
Satisfying management only
Restricting creativity

Correct answer: Ensuring consistency and quality through documented instructions

SOPs provide standardized instructions ensuring consistent quality regardless of which qualified person performs the work.

Question 40: Patient-Reported Outcomes (PROs) in clinical trials must be collected in a standardized way to ensure data validity. Which practice is MOST important?

Translating PRO instruments informally for non-English speaking subjects
Allowing subjects to complete PRO instruments independently before clinical assessments and without coaching (Correct answer)
Having the study coordinator complete PRO forms on behalf of the subject to ensure accuracy
Collecting PRO data only at baseline and end of study

Correct answer: Allowing subjects to complete PRO instruments independently before clinical assessments and without coaching

PROs must be completed independently by subjects before clinical assessments to avoid bias; coaching or staff completion undermines the self-report validity that PROs are designed to capture.

Question 41: A participant in a blinded clinical trial requires emergency surgery and the surgeon needs to know the study drug. What is the correct action?

Use the emergency unblinding procedure to reveal the participant's treatment assignment (Correct answer)
Treat the participant as if on placebo until the blind can be broken formally
Discontinue the participant without unblinding
Contact the sponsor's medical monitor first

Correct answer: Use the emergency unblinding procedure to reveal the participant's treatment assignment

Emergency unblinding procedures exist to protect participant safety; the investigator should use the defined emergency unblinding process immediately.

Question 42: A Data Safety Monitoring Board (DSMB) reviews unblinded interim data in a trial. What is their primary responsibility?

Monitoring for unexpected safety signals and recommending trial continuation, modification, or stopping (Correct answer)
Setting the statistical analysis plan before enrollment
Auditing source documents at investigative sites
Approving protocol amendments submitted by the sponsor

Correct answer: Monitoring for unexpected safety signals and recommending trial continuation, modification, or stopping

The DSMB independently reviews unblinded data to protect participants by recommending trial continuation, modification, or early termination based on safety and efficacy.

Question 43: What is qualitative data in clinical research?

Non-numerical data such as opinions and experiences (Correct answer)
Numerical data
Data collected from lab tests
Data from patient observations

Correct answer: Non-numerical data such as opinions and experiences

Qualitative data in clinical research focuses on understanding the "why" and "how" behind phenomena, capturing rich, descriptive information that cannot be easily quantified. This type of data, often gathered through interviews or focus groups, provides insights into participants' subjective experiences, perceptions, and motivations.

Question 44: A blinded Phase III trial uses placebo control. The study drug is a capsule with a distinctive bitter taste. Participants frequently guess their assignment. This is an example of which methodological problem?

Attrition bias from dropouts
Selection bias in randomization
Detection bias in outcome ascertainment
Unblinding due to pharmacological clues (Correct answer)

Correct answer: Unblinding due to pharmacological clues

Distinctive organoleptic properties such as taste or smell can unblind participants, compromising the integrity of blinding and introducing performance and reporting bias.

Question 45: Which of the following meets the FDA definition of a Serious Adverse Event (SAE) in a clinical trial?

Hospitalization required due to a study-related complication (Correct answer)
A temporary decrease in blood pressure without clinical significance
A minor rash resolving with topical treatment
Mild nausea lasting less than 24 hours

Correct answer: Hospitalization required due to a study-related complication

An SAE is any adverse event that results in death, life-threatening risk, hospitalization, disability, congenital anomaly, or requires medical intervention to prevent serious outcomes.

Question 46: Which scenario represents a violation of the 'attributable' principle in ALCOA documentation standards?

A study staff member corrects an error by crossing it out and initialing with their own initials
A sub-investigator documents a subject visit under their own name
A research coordinator enters data using the principal investigator's login credentials (Correct answer)
A nurse enters CRF data and initials the entry with her own initials

Correct answer: A research coordinator enters data using the principal investigator's login credentials

Using another person's credentials to enter data violates the attributable principle, which requires that data entries be traceable to the individual who actually made them.

Question 47: Which tool is commonly used to screen for cognitive impairment and assess consent capacity in elderly clinical trial subjects?

Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA) (Correct answer)
Patient Health Questionnaire-9 (PHQ-9)
Hamilton Anxiety Rating Scale (HAM-A)
Columbia Suicide Severity Rating Scale (C-SSRS)

Correct answer: Mini-Mental State Examination (MMSE) or Montreal Cognitive Assessment (MoCA)

The MMSE and MoCA are validated cognitive screening tools used to identify cognitive impairment that may affect a subject's capacity to understand and consent to clinical trial participation.

Question 48: During an FDA inspection, an investigator is asked to produce documentation that IP was stored under appropriate conditions throughout the trial. Which record is most directly responsive to this request?

The continuous temperature monitoring logs for the IP storage area (Correct answer)
The signed informed consent forms
The subject screening and enrollment log
The IRB correspondence file

Correct answer: The continuous temperature monitoring logs for the IP storage area

Continuous temperature monitoring logs provide a verifiable record that IP storage conditions remained within protocol-specified ranges for the duration of the study.

Question 49: A participant reveals during an emergency room visit that they are concurrently enrolled in another drug trial without the investigator's knowledge. The investigator should:

Take no action if the participant appears stable
Report the participant to the FDA for protocol violations
Immediately withdraw the participant and destroy their data
Document the dual enrollment, assess safety risks, notify the IRB and sponsor, and determine eligibility impact (Correct answer)

Correct answer: Document the dual enrollment, assess safety risks, notify the IRB and sponsor, and determine eligibility impact

Undisclosed dual enrollment is a protocol deviation that must be documented and reported; the investigator must assess potential drug interactions and inform oversight bodies.

Question 50: Which method is used to account for imbalanced confounders between treatment groups in an observational study?

Blinding of outcome assessors
Propensity score analysis (Correct answer)
Stratified randomization
Intention-to-treat analysis

Correct answer: Propensity score analysis

Propensity score methods (matching, weighting, or stratification) balance measured confounders between groups in observational studies to reduce confounding.

Question 51: Why is regular review important in CPI risk management?

Assessments stay valid forever
Prohibited more than annually
Only needed after incidents
Conditions change and new risks emerge requiring updates (Correct answer)

Correct answer: Conditions change and new risks emerge requiring updates

Regular reviews ensure assessments remain current as conditions change and lessons from incidents are incorporated.

Question 52: In a trial of a topical dermatological agent, systemic absorption is measured to assess safety. The bioavailability is 3%. A participant applies the cream to 40% of their body surface (BSA) due to widespread psoriasis instead of the protocol-specified 10% BSA. What is the safety concern?

No systemic concern as topical drugs do not achieve systemic levels
Decreased local drug concentration due to larger application area
Disproportionate systemic exposure due to increased absorption surface area (Correct answer)
Reduced efficacy due to dilution of the drug across larger skin area

Correct answer: Disproportionate systemic exposure due to increased absorption surface area

Systemic absorption of topical drugs correlates with surface area of application; applying to 4× the protocol BSA can lead to significantly higher systemic exposure and potential systemic toxicity.

Question 53: A clinical trial site is preparing to enroll participants who will receive intrathecal injections. Which sterilization level is required for instruments used in this procedure?

Cleaning only
Sterilization (Correct answer)
High-level disinfection
Low-level disinfection

Correct answer: Sterilization

Instruments entering sterile body spaces (critical items like intrathecal delivery devices) must be sterilized to eliminate all microbial life including spores.

Question 54: Which of the following blood-borne pathogens has the highest transmission risk after a needlestick injury from an infected source?

Hepatitis C virus (HCV)
Hepatitis B virus (HBV) (Correct answer)
Cytomegalovirus (CMV)
HIV

Correct answer: Hepatitis B virus (HBV)

HBV has the highest transmission risk per needlestick (~30%), compared to ~3% for HCV and ~0.3% for HIV.

Question 55: Which document must a CPI investigator sign to commit to conducting the study per GCP and applicable regulations?

Clinical Study Report
Investigator Brochure acknowledgment
Form FDA 1572 (Statement of Investigator) (Correct answer)
IRB approval letter

Correct answer: Form FDA 1572 (Statement of Investigator)

FDA Form 1572 is the Statement of Investigator that formally commits the investigator to conducting the study in compliance with FDA regulations and the protocol.

Question 56: At study completion or early termination, what must happen to unused investigational product?

It must be returned to the sponsor or destroyed per sponsor instructions, with documentation (Correct answer)
It should be donated to a local pharmacy to reduce waste
The investigator may keep it for compassionate use in non-study patients
It is automatically absorbed into the site's general drug inventory

Correct answer: It must be returned to the sponsor or destroyed per sponsor instructions, with documentation

All unused investigational product must be either returned to the sponsor or destroyed under sponsor-approved procedures, and both actions must be fully documented to close out drug accountability.

Question 57: A Phase II dose-ranging trial uses an adaptive design to modify doses based on interim safety data. Which regulatory principle must be maintained to preserve trial integrity?

Post-hoc determination of dose adjustments by the investigator
Unblinded interim analyses by the sponsor's study team
No IRB notification is required for pre-planned adaptations
Pre-specified adaptation rules and maintenance of blinding (Correct answer)

Correct answer: Pre-specified adaptation rules and maintenance of blinding

Adaptive designs must have pre-specified decision rules in the protocol; unplanned adaptations or unblinding of the sponsor team inflate type I error and compromise regulatory acceptability.

Question 58: What is scope creep in CPI project management?

Reducing deliverables
Uncontrolled scope expansion without adjusting time, cost, or resources (Correct answer)
Natural planned growth
Incremental feature addition technique

Correct answer: Uncontrolled scope expansion without adjusting time, cost, or resources

Scope creep adds requirements without formal evaluation, causing schedule delays and budget overruns.

Question 59: What is the principle of respect for persons in ethical research?

Ensuring payment
Respect for their opinions
Voluntary participation and informed consent (Correct answer)
Ensuring non-disclosure

Correct answer: Voluntary participation and informed consent

The principle of respect for persons in ethical research emphasizes the autonomy of individuals and the protection of those with diminished autonomy. This means that participants must voluntarily agree to participate in research, free from coercion or undue influence. Informed consent, where individuals are fully apprised of the study's nature, risks, and benefits before agreeing, is the cornerstone of this principle.

Question 60: Which scale of measurement allows for meaningful ratios between values (e.g., 20 mg is twice 10 mg)?

Nominal
Ratio (Correct answer)
Interval
Ordinal

Correct answer: Ratio

Ratio scales have a true zero point and equal intervals, allowing meaningful ratio comparisons between values.

Question 61: A clinical investigator notices that several participants are not properly completing the study diary, leading to incomplete safety data. What is the BEST course of action?

Re-train participants on diary completion and document the retraining (Correct answer)
Fabricate plausible entries to complete the record
Exclude non-compliant participants from the analysis
Transfer the participants to a different arm of the study

Correct answer: Re-train participants on diary completion and document the retraining

Retraining and documenting the effort ensures data integrity while maintaining participant safety monitoring through complete records.

Question 62: What is the purpose of participant confidentiality in clinical trials?

To ensure privacy and protect sensitive information (Correct answer)
To speed up the trial
To improve recruitment
To avoid exposing data

Correct answer: To ensure privacy and protect sensitive information

Participant confidentiality in clinical trials is essential to protect individuals' privacy and maintain trust in the research process. It involves safeguarding personal and health information collected during a study, ensuring it is not disclosed to unauthorized parties. Upholding confidentiality is a fundamental ethical and legal requirement, preventing potential harm or discrimination to participants.

Question 63: Which element is NOT required in an investigator's SAE narrative report?

Temporal relationship between study drug and event
Treatment given and outcome of the event
Relevant medical history and concomitant medications
Participant's financial status and insurance coverage (Correct answer)

Correct answer: Participant's financial status and insurance coverage

SAE narratives require clinical details including timeline, medical history, concomitant medications, treatment, and outcome—financial or insurance details are irrelevant.

Question 64: A subject in a clinical trial requests to withdraw from the study. What is the investigator's responsibility?

Attempt to persuade the subject to continue to avoid data loss
Respect the subject's decision, stop study procedures, and manage the withdrawal per protocol (Correct answer)
Inform the subject that withdrawal may impact their medical care to encourage continued participation
Notify the FDA within 24 hours of the subject's withdrawal request

Correct answer: Respect the subject's decision, stop study procedures, and manage the withdrawal per protocol

Subjects have the absolute right to withdraw from research at any time without penalty; investigators must respect this right and follow protocol-specified withdrawal procedures.

Question 65: In the context of patient safety in clinical trials, what does the term 'sentinel event' refer to?

A safety signal detected through post-marketing surveillance
A planned interim analysis triggered by enrollment milestones
An unexpected occurrence involving death or serious physical harm that signals a need for immediate investigation (Correct answer)
Any adverse event that is observed by a study monitor

Correct answer: An unexpected occurrence involving death or serious physical harm that signals a need for immediate investigation

A sentinel event is an unanticipated event involving death or serious harm that demands immediate root cause analysis and corrective action.

Question 66: What does residual risk mean in CPI practice?

Risk affecting waste materials
Risk remaining after all controls are implemented (Correct answer)
Budget overrun risk
Initial risk before assessment

Correct answer: Risk remaining after all controls are implemented

Residual risk is the level remaining after practical controls are applied. Some is usually accepted as eliminating all risk is rarely feasible.

Question 67: When a natural disaster disrupts a clinical trial site and participants cannot be reached for scheduled study visits, the investigator's primary obligation is to:

Ensure participant safety and document the force majeure event, notifying the IRB and sponsor (Correct answer)
Wait for sponsor guidance before taking any action
Continue data collection remotely without documenting the disruption
Terminate all participants due to missed visits

Correct answer: Ensure participant safety and document the force majeure event, notifying the IRB and sponsor

In force majeure events, participant safety takes priority; the investigator must document the disruption and notify oversight bodies per protocol and regulatory requirements.

Question 68: Which of the following is a key advantage of an adaptive trial design over a traditional fixed design?

Adaptive designs eliminate the need for IRB oversight
Adaptive designs do not require a statistical analysis plan
Pre-specified modifications to the trial (e.g., sample size, dose) can be made based on interim data without inflating Type I error (Correct answer)
Adaptive trials always produce larger effect size estimates

Correct answer: Pre-specified modifications to the trial (e.g., sample size, dose) can be made based on interim data without inflating Type I error

Adaptive designs allow pre-planned modifications using interim data while controlling Type I error through appropriate statistical methods, increasing efficiency.

Question 69: Which of the following represents an investigator's financial conflict of interest that MUST be disclosed?

Holding equity interest in the company sponsoring the trial (Correct answer)
Receiving standard speaker fees from a medical society unrelated to the trial drug
Being reimbursed for travel to an investigator meeting
Receiving grant funding from NIH for an unrelated study

Correct answer: Holding equity interest in the company sponsoring the trial

Equity interest in the sponsoring company creates a significant financial conflict of interest that must be disclosed to the FDA and IRB per 21 CFR Part 54.

Question 70: Which of the following is an 'additional element' of informed consent under 21 CFR 50.25(b) that must be included when applicable?

Description of benefits to the subject or to others
Statement that significant new findings will be disclosed to the subject (Correct answer)
Description of foreseeable risks or discomforts
Statement that participation is voluntary

Correct answer: Statement that significant new findings will be disclosed to the subject

Disclosure of significant new findings discovered during the study that may affect willingness to continue is an additional element required under 21 CFR 50.25(b) when applicable.

Question 71: Which failure mode is MOST commonly identified in clinical trials through a Failure Mode and Effects Analysis (FMEA)?

Sponsor budget overruns
Insufficient randomization block sizes
Investigator fee payment delays
Process steps that could lead to participant harm if they fail (Correct answer)

Correct answer: Process steps that could lead to participant harm if they fail

FMEA proactively identifies process steps where failure could harm participants, allowing risk mitigation before the trial begins.

Question 72: What is a near-miss report in CPI practice?

A project near deadline
Documentation of an event that could have caused harm but did not (Correct answer)
A near break-even report
An employee near target

Correct answer: Documentation of an event that could have caused harm but did not

Near-miss reports document events where harm almost occurred, providing data to prevent future incidents.

Question 73: A participant taking a study SSRI develops hyperthermia, clonus, agitation, and diaphoresis after self-medicating with tramadol. What is the most likely diagnosis?

Malignant hyperthermia
Serotonin syndrome (Correct answer)
Neuroleptic malignant syndrome
Anticholinergic toxicity

Correct answer: Serotonin syndrome

Tramadol inhibits serotonin reuptake; combined with an SSRI, excess serotonergic activity causes serotonin syndrome characterized by the triad of mental status changes, autonomic instability, and neuromuscular abnormalities.

Question 74: What is the purpose of a placebo in clinical trials?

To monitor side effects
To act as a control group (Correct answer)
To increase patient adherence
To improve the outcome

Correct answer: To act as a control group

The purpose of a placebo in clinical trials is to serve as a control group, allowing researchers to isolate the true effects of the active treatment. A placebo is an inactive substance or treatment that looks identical to the active intervention. By comparing outcomes between the active treatment group and the placebo group, researchers can differentiate between the actual pharmacological effects and effects due to patient expectation or natural disease progression.

Question 75: How should an investigator properly document an adverse event in a Case Report Form (CRF)?

Document all AEs with onset date, duration, severity, relationship to study drug, action taken, and outcome (Correct answer)
Record only events the investigator believes are drug-related
Enter only SAEs; non-serious AEs are tracked informally in site notes
Use standard ICD-10 diagnosis codes exclusively without narrative description

Correct answer: Document all AEs with onset date, duration, severity, relationship to study drug, action taken, and outcome

Complete AE documentation in a CRF requires recording onset date, duration, severity grade, investigator's causality assessment, actions taken, and resolution or outcome.

Question 76: An investigator discovers a protocol deviation that did not harm the subject but was not pre-approved. What is the FIRST action to take?

Amend the informed consent form before notifying anyone
Withdraw the affected subject from the study immediately
Correct the deviation silently and continue the study
Report the deviation to the IRB and sponsor per protocol requirements (Correct answer)

Correct answer: Report the deviation to the IRB and sponsor per protocol requirements

Protocol deviations must be reported to the IRB and sponsor promptly, even if no harm occurred, to maintain study integrity.

Question 77: In a dose-escalation trial, the protocol specifies a 'DLT observation period' of 28 days. What does DLT stand for and why is this period critical?

Drug Limitation Threshold — to assess long-term efficacy
Dose-Limiting Toxicity — to evaluate safety before escalating to the next cohort (Correct answer)
Delayed Laboratory Testing — to confirm biomarker changes
Drug Level Testing — to measure pharmacokinetic parameters

Correct answer: Dose-Limiting Toxicity — to evaluate safety before escalating to the next cohort

DLT (Dose-Limiting Toxicity) observation periods ensure safety data are collected before exposing new subjects to higher doses.

Question 78: What is the purpose of maintaining a subject screening and enrollment log?

To document all subjects screened, reasons for screen failures, and enrolled subject identifiers (Correct answer)
To track site staff training completion
To list all adverse events reported during the trial
To record sponsor monitoring visit dates

Correct answer: To document all subjects screened, reasons for screen failures, and enrolled subject identifiers

Screening and enrollment logs document all subjects considered for the trial, screen failure reasons, and enrolled subject IDs to demonstrate recruitment transparency.

Question 79: What is a clinical research protocol?

A plan that outlines the study's objectives and procedures (Correct answer)
A list of recruited participants
The final report
A written summary of the research findings

Correct answer: A plan that outlines the study's objectives and procedures

A clinical research protocol is a detailed document that serves as the blueprint for a clinical study. It meticulously describes the study's rationale, objectives, design, methodology, statistical considerations, and organizational aspects, ensuring consistency, safety, and scientific integrity throughout the research.

Question 80: In electronic records, 21 CFR Part 11 requires that electronic signatures be:

Linked to their respective electronic records and include the printed name, date/time, and meaning of signature (Correct answer)
Legally binding only if witnessed
Optionally linked to the signer's identity
Applied only by the principal investigator

Correct answer: Linked to their respective electronic records and include the printed name, date/time, and meaning of signature

21 CFR Part 11 mandates that electronic signatures include the printed name of the signer, date/time of signing, and the meaning of the signature (e.g., approval, review).

Question 81: The principal investigator is unreachable when a life-threatening SAE occurs at the clinical site. The sub-investigator should:

Suspend all study activities until the PI returns
Provide emergency care and notify the PI, sponsor, and IRB as required (Correct answer)
Wait for the PI to be available before taking any action
Contact the IRB for authority to act without the PI

Correct answer: Provide emergency care and notify the PI, sponsor, and IRB as required

Sub-investigators are delegated authority to respond to medical emergencies; they must provide care and fulfill reporting obligations while notifying the PI as soon as possible.

Question 82: What does 'informed consent' mean in clinical research?

A medical diagnosis
A written document
A signed agreement after a full understanding (Correct answer)
A verbal agreement

Correct answer: A signed agreement after a full understanding

Informed consent in clinical research means that potential participants receive comprehensive information about the study's purpose, procedures, risks, benefits, and alternatives, and then voluntarily agree to participate. This process involves a detailed discussion with a researcher and signing a document confirming their understanding and willingness to join. It ensures ethical conduct and respects individual autonomy.

Question 83: Which document outlines the globally accepted ethical principles for conducting research involving human subjects that emerged from the Nuremberg trials?

Common Rule (45 CFR 46)
Belmont Report
Declaration of Helsinki
Nuremberg Code (Correct answer)

Correct answer: Nuremberg Code

The Nuremberg Code (1947) established foundational ethical principles for human experimentation, including voluntary consent, after Nazi war crimes.

Question 84: An investigational drug is accidentally administered to a participant at twice the protocol-specified dose. This event results in hospitalization. How should this be classified?

Serious adverse event requiring expedited reporting to IRB and sponsor (Correct answer)
Near-miss incident requiring internal documentation only
Protocol deviation only, since it was an accident
Adverse event requiring standard 30-day reporting to FDA

Correct answer: Serious adverse event requiring expedited reporting to IRB and sponsor

Hospitalization resulting from a medication error meets the definition of a serious adverse event (SAE), requiring expedited reporting to both the sponsor and IRB.

Question 85: What is an investigator's responsibility regarding investigational product (IP) accountability?

Document only IP that is dispensed to subjects; unused product need not be tracked
Accountability is solely the pharmacy's responsibility at institutional sites
Maintain accurate records of IP receipt, use, and disposition, and allow sponsor access to these records (Correct answer)
Return all unused IP to the sponsor without maintaining records

Correct answer: Maintain accurate records of IP receipt, use, and disposition, and allow sponsor access to these records

Investigators must maintain complete IP accountability records including receipt, dispensing, and returns, and allow sponsor and regulatory access for audit.

Question 86: In a multi-site clinical trial, one site reports an unusually high rate of surgical site infections (SSIs). The FIRST step in investigation should be:

Conduct a root cause analysis of aseptic technique and processes (Correct answer)
Report the site to the FDA
Increase antibiotic prophylaxis doses
Suspend enrollment at the site

Correct answer: Conduct a root cause analysis of aseptic technique and processes

Root cause analysis of procedural technique, sterility practices, and environmental factors is the first step to identify and correct the source of excess SSIs.

Question 87: Which of the following best describes the Hawthorne effect in clinical research?

Investigators inadvertently influence data collection
Study drugs cause unexpected behavioral changes
Drop-out rates increase when participants feel monitored
Participants improve outcomes simply because they know they are being observed (Correct answer)

Correct answer: Participants improve outcomes simply because they know they are being observed

The Hawthorne effect refers to the tendency for study participants to modify their behavior merely because they are being observed, potentially inflating outcomes.

Question 88: A Data Safety Monitoring Board (DSMB) recommends immediate trial suspension due to a safety signal. The investigator's responsibility is to:

Immediately halt enrollment and notify all participants currently on study drug (Correct answer)
Continue enrolling until the sponsor issues an official stop order
Await IRB confirmation before stopping any study activities
Continue only with participants already enrolled but stop new enrollment

Correct answer: Immediately halt enrollment and notify all participants currently on study drug

Upon a DSMB safety-based suspension recommendation communicated through the sponsor, investigators must immediately halt enrollment and take steps to protect current participants.

Question 89: A clinical trial participant becomes incapacitated mid-study and can no longer provide ongoing consent. The investigator should:

Consult the IRB before taking any action
Obtain consent from a legally authorized representative and reassess continued participation (Correct answer)
Discontinue all study procedures immediately without LAR consultation
Continue study procedures as originally consented

Correct answer: Obtain consent from a legally authorized representative and reassess continued participation

When a participant loses capacity, a legally authorized representative must be engaged to provide proxy consent before study procedures continue.

Question 90: Under what circumstance may an investigator implement a protocol change without prior IRB approval?

When the change is necessary to eliminate an immediate hazard to a research subject (Correct answer)
When fewer than 10% of subjects are affected by the change
When the sponsor has approved the change in writing
When the IRB has not responded within 30 days of the amendment submission

Correct answer: When the change is necessary to eliminate an immediate hazard to a research subject

An investigator may implement a protocol change without prior IRB approval only when necessary to eliminate an immediate hazard to subjects, followed by prompt IRB notification.

Question 91: During a monitoring visit, a sponsor's clinical research associate (CRA) finds undocumented protocol deviations that may have affected participant safety. What is the MOST appropriate next step?

Document the findings in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPAs) (Correct answer)
Correct the records retroactively without informing the IRB
Ignore minor deviations that did not result in harm
Immediately terminate the site without further review

Correct answer: Document the findings in the monitoring report and work with the investigator to implement corrective and preventive actions (CAPAs)

Monitoring findings must be documented and addressed through formal CAPA processes to correct deficiencies and prevent recurrence.

Question 92: A participant in a phase II trial reports chest pain. Which action reflects the correct order of priorities for a CPI?

Provide immediate medical care, document the event, then notify the sponsor and IRB (Correct answer)
Consult the protocol stopping rules before initiating any treatment
Document the symptom, call the sponsor, then provide care
Notify the IRB, obtain emergency IRB approval, then treat the participant

Correct answer: Provide immediate medical care, document the event, then notify the sponsor and IRB

The correct order is: immediate medical care first, then thorough documentation and timely notification to sponsor and IRB.

Question 93: An investigational drug trial site experiences a fire drill that disrupts temperature-controlled storage, potentially compromising investigational product integrity. What is the correct response regarding patient safety?

Continue dispensing the product since the disruption was brief
Quarantine the potentially compromised product, notify the sponsor, and follow the protocol's temperature excursion procedures before any further dispensing (Correct answer)
Wait for the next monitoring visit to address the issue
Discard all product and re-enroll participants on fresh product without documentation

Correct answer: Quarantine the potentially compromised product, notify the sponsor, and follow the protocol's temperature excursion procedures before any further dispensing

Temperature excursions require quarantine and sponsor notification to assess product viability before dispensing, protecting participants from potentially degraded study drug.

Question 94: What should an investigator do if they believe the sponsor's monitoring visit findings are inaccurate?

Accept the findings as the sponsor's monitor is the regulatory authority
Discuss the discrepancy with the monitor and document their position in writing (Correct answer)
Refuse to sign the monitoring report until all discrepancies are resolved
Sign the monitoring report under protest and file a formal grievance with the FDA

Correct answer: Discuss the discrepancy with the monitor and document their position in writing

Investigators should resolve disagreements with monitors through professional dialogue and document their position in writing for the record.

Question 95: An IRB operates under an FDA-approved assurance. What does the IRB's continuing review obligation require?

Quarterly site visits to all research locations under the assurance
Monthly review of all adverse event reports from all active studies
A full board review of all enrolled participant records at 6-month intervals
Review of ongoing studies at intervals appropriate to the degree of risk, but at least annually (Correct answer)

Correct answer: Review of ongoing studies at intervals appropriate to the degree of risk, but at least annually

Under 21 CFR 56.109, IRBs must conduct continuing review of approved research at intervals appropriate to risk, but no less than once per year.

Question 96: In clinical trial statistics, a p-value of 0.03 means:

The study has 97% power to detect the effect
There is a 3% probability of observing results at least as extreme as those obtained, assuming the null hypothesis is true (Correct answer)
The treatment effect is clinically meaningful
There is a 3% probability that the null hypothesis is true

Correct answer: There is a 3% probability of observing results at least as extreme as those obtained, assuming the null hypothesis is true

A p-value quantifies the probability of obtaining the observed (or more extreme) results under the null hypothesis; it does not directly state the probability that the null hypothesis is true.

Question 97: A biomarker-stratified clinical trial requires tumor tissue collection at baseline. A subject's archival biopsy is 4 years old. The protocol requires tissue collected 'within 3 years of enrollment.' What should the investigator do?

Use the archival tissue since it is close to the 3-year window
Enroll the subject and document the deviation
Obtain a new biopsy or consult the sponsor, as the archival sample does not meet protocol requirements (Correct answer)
Request a protocol waiver from the IRB on the subject's behalf

Correct answer: Obtain a new biopsy or consult the sponsor, as the archival sample does not meet protocol requirements

The archival tissue falls outside the protocol-specified 3-year window; the investigator must obtain fresh tissue or contact the sponsor for guidance before enrollment.

Question 98: Which of the following is an example of information bias in clinical research?

Imbalanced baseline characteristics between groups
Exclusion of non-English-speaking participants
Systematic over-reporting of symptoms in one exposure group (Correct answer)
Differential loss to follow-up between treatment arms

Correct answer: Systematic over-reporting of symptoms in one exposure group

Information bias arises when data are collected or recorded differently across groups, such as when exposed participants are questioned more thoroughly about symptoms.

Question 99: At what reading level should informed consent documents ideally be written, per FDA and OHRP guidance?

8th grade or below (Correct answer)
Graduate level for complex medical studies
10th grade
College level (12th grade)

Correct answer: 8th grade or below

FDA and OHRP recommend consent documents be written at an 8th-grade reading level or below to ensure comprehension across diverse subject populations.

Question 100: Under GCP guidelines, which document formally authorizes staff to manage emergencies at a clinical trial site?

The site's delegation of authority log signed by the PI (Correct answer)
The protocol signature page
The FDA Form 1572
The IRB approval certificate

Correct answer: The site's delegation of authority log signed by the PI

The delegation of authority log specifies which staff members are authorized to perform specific study tasks, including emergency medical response procedures.

Question 101: What is a statistical test used for in clinical research?

To assess if findings are significant and generalizable (Correct answer)
To recruit participants
To monitor patient symptoms
To improve patient outcomes

Correct answer: To assess if findings are significant and generalizable

Statistical tests are applied in clinical research to analyze collected data and determine the probability that observed results occurred by chance. They help researchers assess the statistical significance of their findings, allowing them to draw valid conclusions about the effectiveness of interventions and their generalizability to the target population.

Question 102: In a clinical trial, a participant develops a catheter-associated urinary tract infection (CAUTI). Which organism is most commonly implicated in CAUTIs?

Escherichia coli (Correct answer)
Pseudomonas aeruginosa
Staphylococcus aureus
Candida albicans

Correct answer: Escherichia coli

E. coli is the most common causative pathogen in catheter-associated urinary tract infections.

Question 103: What is MedWatch, and when is it used in the context of clinical research?

The FDA's safety reporting program for reporting serious problems with human medical products (Correct answer)
A real-time patient monitoring app used during clinical trials
A regulatory database for tracking IND submissions
A consent monitoring tool used by IRBs

Correct answer: The FDA's safety reporting program for reporting serious problems with human medical products

MedWatch is the FDA's Safety Reporting Program, used to report serious adverse events, product quality problems, and medication errors involving FDA-regulated products.

Question 104: A participant in a pain management trial tells the investigator they want to join because they are desperate and have no other treatment options. This situation raises concern primarily about:

Sponsor financial conflicts
Inadequate blinding procedures
Voluntariness of consent due to therapeutic desperation (Correct answer)
Study eligibility criteria being too broad

Correct answer: Voluntariness of consent due to therapeutic desperation

Therapeutic desperation can compromise the voluntariness required for valid informed consent, as participants may feel coerced by lack of alternatives.

Question 105: When evaluating inclusion/exclusion criteria, a physician investigator discovers a subject meets all inclusion criteria but has one exclusion criterion that appears borderline. What is the appropriate next step?

Contact the sponsor or medical monitor for clarification before enrolling (Correct answer)
Enroll the subject and document the deviation
Have the subject sign the consent form and decide eligibility after enrollment
Exclude the subject without further inquiry

Correct answer: Contact the sponsor or medical monitor for clarification before enrolling

Borderline eligibility situations require consultation with the sponsor or medical monitor before enrollment to protect subject safety and protocol integrity.

Question 106: Which of the following best describes 'data lock' (database lock) in a clinical trial?

Archiving the database at the end of the retention period
Finalizing and freezing the database after all queries are resolved so no further changes can be made before analysis (Correct answer)
Locking individual CRF pages as they are completed at each visit
Encrypting the database to prevent unauthorized access during the trial

Correct answer: Finalizing and freezing the database after all queries are resolved so no further changes can be made before analysis

Database lock is the point at which all queries are resolved and the database is frozen, ensuring the analysis dataset cannot be altered.

Question 107: A trial site is conducting a study involving participants with active pulmonary tuberculosis. Staff entering participant rooms should wear at minimum a:

N95 filtering facepiece respirator (Correct answer)
Powered air-purifying respirator (PAPR)
Standard surgical mask
Face shield alone

Correct answer: N95 filtering facepiece respirator

An N95 respirator is the minimum respiratory protection required for entering rooms of patients with suspected or confirmed pulmonary TB.

Question 108: What is the significance of the Declaration of Helsinki?

It monitors drug side effects
It is a financial guideline
It outlines recruitment methods
It provides a regulatory framework for ethical research (Correct answer)

Correct answer: It provides a regulatory framework for ethical research

The Declaration of Helsinki is a set of ethical principles regarding human experimentation developed by the World Medical Association. It is widely regarded as the cornerstone document for ethical research involving human subjects, influencing national and international regulations. The Declaration emphasizes the importance of informed consent, risk-benefit assessment, and the protection of vulnerable populations.

Question 109: What is evidence-based practice in CPI Pharmacology & Medication Management?

Using newest unproven methods
Following intuition only
Doing whatever clients request
Integrating research evidence with expertise and client needs (Correct answer)

Correct answer: Integrating research evidence with expertise and client needs

Evidence-based practice combines research, expertise, and client preferences for optimal outcomes.

Question 110: During screening, a subject's medical history reveals they completed chemotherapy 6 weeks ago. The protocol requires a 4-week washout for prior chemotherapy. What is the correct action?

Consult the sponsor before enrolling since 6 weeks is close to the required interval
Exclude the subject because washout periods are approximate and need a safety margin
Enroll the subject immediately since 6 weeks exceeds the washout period (Correct answer)
Delay enrollment by an additional 4 weeks to ensure full washout

Correct answer: Enroll the subject immediately since 6 weeks exceeds the washout period

The subject completed chemotherapy 6 weeks ago, which exceeds the required 4-week washout period, making them eligible based on this criterion.

Question 111: What is the key difference between a 'protocol deviation' and a 'protocol violation' in clinical research?

Violations are reported to the FDA; deviations are reported only to the sponsor
A deviation is a minor unplanned departure; a violation is a significant departure that may affect subject safety or data integrity (Correct answer)
A deviation is intentional; a violation is unintentional
A deviation affects eligibility criteria; a violation affects study procedures

Correct answer: A deviation is a minor unplanned departure; a violation is a significant departure that may affect subject safety or data integrity

A protocol deviation is a minor unplanned departure from the approved protocol, while a protocol violation is a significant departure that may impact subject safety, rights, or the integrity of study data.

Question 112: A study drug is a potent inhibitor of P-glycoprotein (P-gp). A participant is concurrently taking digoxin. What is the expected drug-drug interaction?

No change in digoxin levels
Accelerated digoxin renal excretion
Decreased digoxin plasma concentrations
Increased digoxin plasma concentrations (Correct answer)

Correct answer: Increased digoxin plasma concentrations

P-gp normally effluxes digoxin from enterocytes and renal tubular cells; P-gp inhibition increases digoxin absorption and reduces its secretion, raising plasma levels.

Question 113: In a pragmatic clinical trial, the study conditions are designed to:

Minimize variability by excluding co-morbid patients
Maximize internal validity by using strict eligibility criteria
Test pharmacokinetics under controlled laboratory conditions
Reflect real-world clinical practice and diverse patient populations (Correct answer)

Correct answer: Reflect real-world clinical practice and diverse patient populations

Pragmatic trials prioritize external validity by enrolling broad populations and allowing routine clinical flexibility, contrasting with explanatory (efficacy) trials.

Question 114: An investigator is designing a First-in-Human (FIH) trial. The starting dose is calculated using the NOAEL from animal studies. The human equivalent dose (HED) is derived by:

Applying a fixed 10-fold safety factor to the animal ED50
Dividing the animal NOAEL by an allometric scaling factor based on body surface area (Correct answer)
Multiplying the animal NOAEL by the animal's body weight in kg
Using the animal NOAEL directly without adjustment

Correct answer: Dividing the animal NOAEL by an allometric scaling factor based on body surface area

HED is calculated by dividing the animal NOAEL (in mg/kg) by a body surface area conversion factor (Km ratio), then applying a safety factor to determine the maximum recommended starting dose.

Question 115: An investigator receives a monitoring visit and the monitor requests access to original medical records to verify CRF data. The investigator should:

Provide only photocopies, never originals
Deny access to protect subject confidentiality
Allow access, ensuring subject identifiers are handled per the consent form and applicable regulations (Correct answer)
Require the monitor to submit a written request 30 days in advance

Correct answer: Allow access, ensuring subject identifiers are handled per the consent form and applicable regulations

Monitors have the right to access source documents as permitted by the subject's consent form and applicable regulations; the site must facilitate this access.

Question 116: Emergency research conducted under 21 CFR 50.24 (exception from informed consent) requires which prospective community consultation step?

Signed consent from community representatives
Written agreement from local hospital administrators
Public disclosure and community consultation before initiating the research (Correct answer)
IRB waiver of the community consultation requirement

Correct answer: Public disclosure and community consultation before initiating the research

21 CFR 50.24 mandates prospective community consultation and public disclosure as prerequisites before conducting exception from informed consent research.

Question 117: A randomized controlled trial uses a PROBE design. What does PROBE stand for?

Placebo-controlled Randomized Observational Blinded Evaluation
Prospective Randomized Outcome-Based Evaluation
Parallel Randomized Open-label Blinded Efficacy
Prospective Randomized Open Blinded End-point (Correct answer)

Correct answer: Prospective Randomized Open Blinded End-point

PROBE (Prospective Randomized Open Blinded End-point) uses open-label treatment assignment but blinded endpoint assessment to reduce bias.

Question 118: How long must clinical investigators retain study records after the completion or discontinuation of the clinical investigation under FDA regulations?

5 years after study completion regardless of marketing status
1 year after study completion
2 years after the date a marketing application is approved or discontinued (Correct answer)
Until the IRB formally closes the study file

Correct answer: 2 years after the date a marketing application is approved or discontinued

Under 21 CFR 312.62, investigators must retain records for 2 years after the date a marketing application is approved or after investigation is discontinued.

Question 119: Which of the following best describes the 'stopping rules' in a clinical trial protocol?

Predefined criteria that trigger immediate discontinuation of a participant or the entire trial (Correct answer)
FDA-mandated timelines for IND withdrawal
Sponsor authority to end the trial for business reasons
Guidelines for when the IRB can revoke site approval

Correct answer: Predefined criteria that trigger immediate discontinuation of a participant or the entire trial

Stopping rules are pre-specified safety thresholds in the protocol that mandate participant withdrawal or trial suspension when specific adverse events or data patterns occur.

Question 120: According to the CONSORT statement, what must be reported in a randomized trial publication to ensure transparency?

Results from the per-protocol population only
Sponsor funding sources only
Details of randomization, blinding, participant flow, and all pre-specified outcomes (Correct answer)
Only the primary outcome and p-value

Correct answer: Details of randomization, blinding, participant flow, and all pre-specified outcomes

CONSORT (Consolidated Standards of Reporting Trials) requires comprehensive reporting of trial design, conduct, and analysis to minimize reporting bias.

Question 121: An investigational monoclonal antibody has a volume of distribution (Vd) of 4 L in a 70 kg participant. What does this indicate about the drug's distribution?

The drug is largely confined to plasma and does not distribute into tissues (Correct answer)
The drug extensively distributes into peripheral tissues
The drug crosses the blood-brain barrier efficiently
The drug is primarily stored in adipose tissue

Correct answer: The drug is largely confined to plasma and does not distribute into tissues

A Vd of approximately 4 L approximates plasma volume, indicating that large molecules like monoclonal antibodies remain predominantly in the vascular compartment due to their size.

Question 122: What is the purpose of randomization codes or the randomization list in a clinical trial?

To rank subjects by likelihood of completing the study
To assign subjects to treatment arms in an unpredictable manner to minimize selection bias (Correct answer)
To prioritize enrollment of subjects with the most severe disease
To determine which subjects will receive placebo based on insurance coverage

Correct answer: To assign subjects to treatment arms in an unpredictable manner to minimize selection bias

Randomization assigns subjects to treatment groups in an unpredictable, unbiased way, ensuring that known and unknown confounders are evenly distributed across groups.

Question 123: A Phase I dose-escalation study in oncology most commonly uses the 3+3 design to determine the:

Pharmacokinetic half-life
Minimum effective dose
Maximum tolerated dose (MTD) (Correct answer)
Recommended Phase III dose

Correct answer: Maximum tolerated dose (MTD)

The 3+3 design escalates doses in cohorts of three patients and defines the MTD based on dose-limiting toxicity occurrence.

Question 124: What is the role of the Statistical Analysis Plan (SAP) in a clinical trial?

To summarize results for submission to the FDA after the trial
To describe how participants will be randomized and enrolled
To pre-specify in detail all statistical methods, endpoints, and analyses before unblinding to prevent data-driven bias (Correct answer)
To outline the monitoring visit schedule for the sponsor

Correct answer: To pre-specify in detail all statistical methods, endpoints, and analyses before unblinding to prevent data-driven bias

The SAP is finalized before unblinding and specifies all analytical methods, ensuring analyses are not influenced by knowledge of outcomes.

Question 125: Under 21 CFR Part 56, which of the following circumstances allows an IRB to conduct expedited review rather than full board review?

Research involving no more than minimal risk and falling within FDA-designated categories of research (Correct answer)
Any study amendment that does not change the primary endpoint
All continuation studies where no protocol changes have been made
Any Phase I clinical trial involving investigational drugs in adults

Correct answer: Research involving no more than minimal risk and falling within FDA-designated categories of research

Expedited review is permitted for minimal-risk research that falls within FDA-published categories or for minor changes to previously approved research.

Certified Principal Investigator (CPI®)

The CPI® certification validates the expertise of physicians and advanced practice clinicians serving as principal investigators in clinical trials, covering GCP compliance, ethical conduct, site management, and data integrity across all phases of clinical research.

125

Questions

180 min

Time Limit

70%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds